LianBio
PublicLianBio is now publicly traded
The data on this page reflects LianBio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 31, 2021
Last Round
Series A
Oct 29, 2020
Total Funding Raised
$635M
Company Overview
LianBio (NAS: LIAN) is a biopharmaceutical company focused on developing and commercializing innovative medicines for patients with unmet medical needs, primarily through in-licensing assets for Greater China and other Asian markets, while advancing a diverse portfolio of clinically validated product candidates across various therapeutic areas including cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.
Sector
Biotech
AI Layer
Non-AI
Keywords
LianBio Comparables
Compare LianBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Expedition Therapeutics | 51% |
LianBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Oct 31, 2021 | ||||
| Series A | Oct 29, 2020 | ||||
| Seed | Aug 11, 2020 |
LianBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| Farallon Capital Management | Series A |
| Perceptive Advisors | Series A, Seed |
| Vida Ventures | Series A |
| Travilah Consulting Group | Series A |
| Tybourne Capital Management | Series A |
| Logos Capital | Series A |
LianBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access